Background. Fibroblast growth factor (FGF)-23, a novel bone-derived phosphaturic factor involved in mineral metabolism, is increased in chronic kidney disease (CKD); in dialysis patients, it has been linked to increased mortality rates and vascular calcification (VC). The present investigation aimed to study the factors associated with elevated serum FGF-23 levels in patients treated with long haemodialysis (LHD) sessions and to determine whether a relationship exists between serum FGF-23 levels and patient survival. The effect of FGF-23 on the 2-year survival rate was assessed using the Cox proportional hazard model, adjusted for confounding variables and according to the serum phosphate tertiles. Results. The study included 219 patients. Serum FGF-23 levels were high: 7060 ± 13 500 RU/mL (median, 2740 RU/mL). In logistical regressions, only calcaemia (P = 0.002), phosphataemia (P = 0.008) and warfarin use (P = 0.04) were associated with the highest FGF-23 quartile. In the subgroup of patients with an estimated VC score, the third and fourth quartiles of the FGF-23 levels were associated with more severe VC. In multivariate linear regressions, only phosphataemia remained significantly correlated with FGF-23 (P = 0.04). The 2-year mortality rate was significantly higher for haemodialysis patients with serum FGF-23 levels in the higher quartile [P = 0.007; hazard ratio, 2.5 (1.3-5)] than in the first quartile, whereas within the phosphataemia tertiles, the lowest serum FGF-23 quartile was associated with lowered mortality. Conclusion. This study demonstrated a high level of circulating FGF-23 in LHD patients, despite infrequent hyperphosphataemia. However, phosphataemia is still the main factor correlating with serum FGF-23. The association of higher serum FGF-23 levels with mortality and VC, regardless of the serum phosphate levels, has thus been confirmed.
Introduction
Fibroblast growth factor 23 (FGF-23), a novel hormone produced by osteoblasts, is involved in the regulation of phosphate and the metabolism of vitamin D. FGF-23 was first identified as the cause of a rare hypophosphataemic syndrome accompanied by phosphaturia, a low 1,25(OH) 2 D serum level and osteomalacia [1] . FGF-23 causes renal phosphate wasting by inhibiting the sodium phosphate cotransporter type IIa (NPT2a) in the renal proximal tubule; moreover, it also suppresses the renal expression of CYP27B1, resulting in the impairment of 1,25(OH) 2 D synthesis [2] . Further, FGF-23 binds to its receptor via Klotho, a protein produced by the kidney [3] .
In chronic kidney disease (CKD), FGF-23 levels rise as the glomerular filtration rate (GFR) declines and phosphate accumulates [4] , which, in turn, results in increased renal phosphate excretion and reduced dietary phosphate absorption via 1,25(OH) 2 D inhibition [5] . In haemodialysis (HD) patients, it has been suggested that high levels of serum FGF-23 are associated with the reduced expression of Klotho [6] . Recent studies have established a relationship between dietary phosphate and serum FGF-23 levels [7] and have shown that phosphate binders reduce FGF-23 levels in HD patients [8] .
FGF-23 null mice exhibit increased cardiovascular calcification that is associated with hyperphosphataemia and excess 1,25(OH) 2 D levels and die prematurely [9, 10] . The FGF-23-Klotho axis seems to protect against cardiovascular disease and premature ageing, and the compensatory increase in FGF-23 may prevent vascular calcification FGF-23 and related mortality 2793 (VC) and reduce cardiovascular mortality (CVM). In contrast, CKD patients-who have elevated serum FGF-23 levels-exhibit increased levels of CVM and VC [9] . Additionally, we previously reported a correlation between VC and serum FGF-23 levels [11] . Furthermore, a correlation between serum FGF-23 levels and mortality, which was independent of phosphataemia, has been recently reported in HD patients [12] .
Long HD (LHD) results in better control of hyperphosphataemia and use of less phosphate binders [13] . The present study aimed to identify the factors associated with serum FGF-23 levels in LHD and their effect on the 2-year survival rate at our HD centre.
Methods
All HD patients treated in our centre from September 2006 were included in the study and prospectively observed over 2 years. All clinical data were collected, including the standard laboratory values, which were recorded using the mean of the previous 3 months; medical history; cardiovascular events and risk factors; medication [statins, angiotensinconverting enzyme (ACE) inhibitors, warfarin, vitamin D, cinacalcet and phosphate binders]; and some bone-specific markers, including osteoprotegerin (OPG, ELISA; BioVendor Inc., Brno, Czech Republic), bone alkaline phosphatase (BALP, chemiluminescence; Beckmann Inc., Urbana, IL, USA) and β-crosslaps (CTX, chemiluminescence; Roche R , Basel, Switzerland). Parathyroid hormone (PTH) was measured using a secondgeneration assay (Elecsys; Roche R ), and FGF-23 was measured using a Cterminal assay (FGF-23 (C-Term) ELISA, Immutopics Inc., San Clemente, CA, USA). Serum 25(OH) vitamin D was measured using a chemiluminescence assay (LIAISON R ; DiaSorin Inc., Stillwater, MN, USA). Total calcium, not corrected for albumin or protein, was recorded. All samples were collected before a mid-week HD session. Kt/Vsp was calculated monthly using the Daugirdas 2 formula. Patients received haemodialysis three times a week on a 5-to 8-h schedule, using a dialysate calcium concentration of 1.5 mmol/L in >80% of patients and, randomly, a polysulphone low (FX8 and FX10, Helixone R ; Fresenius S.E., Bad-Homburg, Germany) or high-flux (FX80 and FX100) filter, switched during the study, to preclude any survival bias. A subgroup of patients (n = 161) with a recent peripheral VC score, as described previously [11] , was analysed individually, according to the serum FGF-23 level. Each patient's radiological semi-quantitative score ranged from 0 to 3, according to the severity and extent of the VC from eight fine-detail plain radiographic films (front pelvis, profile lumbar and knee, right hand and arm, chest, skull and orthopantomogram).
Statistical analysis
One-way analysis of variance with Duncan's post hoc multiple comparison test was used to compare the variables according to quartiles of serum FGF-23 levels. Fisher's exact test was applied for proportion comparisons. Logistical regression was used for factors associated with the highest serum FGF-23 quartile versus the other quartiles. Monovariate regression analyses were used for continuous variables against log FGF-23, while multiple regression analyses were applied between log FGF-23 levels and the significant factors identified in the monovariate analysis. The 2-year survival rates according to the quartile values of serum FGF-23 were calculated, using the Cox proportional hazard model adjusted for age, gender, diabetes, tobacco use, alfacalcidol use, dialysis vintage, serum albumin, tertile of phosphataemia, calcaemia and PTH values. Patients were censored if they died. Odds ratios (OR) for death were compared within the tertiles of phosphataemia, between the lowest quartile and the three higher FGF-23 quartiles. Results are reported as mean ± standard deviations. Differences with P-values ≤ 0.05 were considered statistically significant. Statistical analyses were performed using MedCalc C software, version 9.3.1.0 (Belgium).
Results
A total of 219 HD patients were studied. The mean age was 66.6 ± 14 years; 43% were female, and 35% were diabetic. The duration of dialysis was 68 ± 75 months, with a native AV-fistula in 86% of patients and a mean Kt/Vsp of 2.4 ± 0.9; hyperphosphataemia of >1.8 mmol/L was found in only 11% of the cases. Treatments included CaCO 3 (11%), sevelamer (37%), alfacalcidol (48%), 25(OH)D 3 (93%), cinacalcet (12%), warfarin (20%) and erythropoietin (72%). The mean erythropoietin dose was 150 U/(kg week), achieving a mean haemoglobin (Hb) serum level of 11.4 g/dL; less than 10% of patients had serum Hb < 10 g/dL.
The mean serum FGF-23 level was 7060 ± 13 500 RU/mL (median, 2740 RU/mL; interquartile range, 1192-8667 RU/mL). Patients with a 3 × 5-h schedule (n = 110) had a median serum FGF-23 level of 2539 (882-8498) RU/mL versus 2737 (1321-9789) RU/mL in patients with the 3 × 8-h (n = 80) schedule. There was no difference in phosphataemia between the two dialysis schedules (1.47 ± 0.4 versus 1.37 ± 0.4 mmol/L).
Patient characteristics and biological and treatment data are shown in Table 1 , according to the FGF-23 quartiles. Patients in the fourth quartile were younger and more frequently administered warfarin, alfacalcidol, sevelamer and cinacalcet. Their serum levels of PTH, calcium, Ca × P product and phosphate were higher. In logistical regressions, only calcaemia [OR: 3.5; 95% confidence interval (CI): 2.1-6.2; P = 0.002], phosphataemia (OR: 5; 95% CI: 2-12.2; P = 0.008) and warfarin use (OR: 2; 95% CI: 1.05-3.9; P = 0.04) were associated with the highest FGF-23 quartile. In the subgroup of patients having a measure of their VC score, the third and fourth FGF-23 quartiles were associated with more severe peripheral VC.
Univariate linear regressions showed a significant correlation between log FGF-23 and age (r 2 = −0.02; P = 0.04), serum C-reactive protein (CRP) (r 2 = 0.02; P = 0.02), iPTH (r 2 = 0.02; P = 0.02), calcaemia (r 2 = 0.06; P < 0.001), phosphataemia (r 2 = 0.11; P < 0.001, Figure 1 ) and Ca × P product (r 2 = 0.13; P < 0.001), but not with the weekly dose of alfacalcidol. In multivariate regressions that included all the aforementioned parameters, only phosphataemia remained significantly correlated with FGF-23 (P = 0.04).
Thirty-three patients were lost to follow-up. The median time of follow-up was 695 days. The total number of deaths was 48, with an annual mortality rate of 13%. The results of the survival analysis are shown in Figure 2 , with the 2-year survival rate being significantly lower for HD patients with serum levels of FGF-23 in the highest quartile (P = 0.007, hazard ratio, 2.5 [1. [3] [4] [5] ) than in the first quartile; tertiles of phosphataemia, on the other hand, were not related to survival. While plotting the 2-year OR of mortality against tertiles of phosphataemia and comparing the lowest FGF-23 quartile with the three higher quartiles showed a better survival rate in the lowest one, it was significant only in the first tertile of phosphataemia ( Figure 3 ). 
Discussion
In this cross-sectional analysis of 2-year survival in LHD patients at our centre, we confirmed that serum FGF-23 levels were high and that they were associated with both increased serum phosphate levels and mortality. In CKD, FGF-23 levels increase with increasing phosphataemia and PTH and decreasing GFR [14] . Urena phosphataemia but not with PTH levels [15] . The present study confirms high levels of serum FGF-23 in HD patients, even in those patients on LHD who have less hyperphosphataemia; however, there is a strong correlation with the mean 3-month serum phosphate level. In monovariate regression analyses, a weak relationship was found between the serum FGF-23 and PTH levels; it was not significant in multivariate analyses. FGF-23 has been reported to be a major independent risk factor for refractory hyperparathyroidism (HPT) in dialysis patients [16] ; it is probably related to impaired 1,25(OH) 2 D synthesis and phosphate overload. In cases of severe secondary HPT and after parathyroidectomy, FGF-23 correlates with calcium and PTH [17] . Indeed, it has been hypothesized that FGF-23 and PTH can regulate each other [18, 19] . In end-stage renal disease (ESRD) patients, the hypophosphataemic effect of FGF-23 via the kidneys is reduced, but the effect on 1,25(OH) 2 D synthesis remains significant [4] , which may favour secondary HPT. Even if 1,25(OH) 2 D synthesis is reduced, 1α-hydroxylation continues after 25(OH)D 3 supplementation in HD patients, as shown in our previous study [20] . It is unclear whether FGF-23 can regulate 1α-hydroxylase gene expression in cells other than renal tubular cells.
The greater use of alfacalcidol in the highest FGF-23 quartile may be related to vitamin D, which is administered to treat secondary HPT and its effect of increasing phosphate absorption; intravenous calcitriol has been shown to increase FGF-23 in HD patients [21] , but the effect of large doses of native vitamin D supplementation on FGF-23 levels has not been studied. The use of cinacalcet also indicates treatment for secondary HPT, as well as the use of sevelamer for hyperphosphataemia. The relationship between serum FGF-23 and serum calcium, which has not been reported in other studies, may be due to the larger vitamin D doses, both native and/or active, administered to the patients in this study.
The association of warfarin use with FGF-23 levels has not been previously reported. In our experience, warfarin use is associated with VC [11] . It has been hypothesized that the effect of matrix Gla protein (MGP), a vitamin K-dependent inhibitor of VC, is impaired during warfarin treatment. We previously reported that FGF-23 is associated with peripheral VC [11] , and the apparent link between warfarin and FGF-23 may be through their association with VC. Our previous study confirmed that severe VC is associated with premature mortality [11] , and it may link FGF-23 with mortality. Unlike in ESRD patients, in patients with near-normal renal function, serum FGF-23 has not been found to correlate with cardiac calcification [22] .
The association between FGF-23 and VC in HD patients may not reflect a direct effect of FGF-23 on the vasculature; more likely, it is due to toxicity from other factors such as hyperphosphataemia and excessive use of active vitamin D. An association between FGF-23 and mortality has been reported in HD patients in a US population with more prevalent hyperphosphataemia [12] but who were not taking active vitamin D. In that study, Gutierrez et al. found that the higher FGF-23 quartile was associated with increased mortality at every serum phosphate level [12] , as was also noted in the present study. It was concluded that phosphataemia is only part of the risk assessment attributable to abnormal phosphate metabolism, especially in the normal range [23] . Further study is necessary to assess the efficacy of measuring serum FGF-23 levels as a measure of phosphate overload.
This study has several limitations. Its cross-sectional nature allows for neither the determination of changes in serum FGF-23 levels nor their effect on prognosis. The particular dialysis strategy of our centre-which results in fewer cases of hyperphosphataemia, reduced use of phosphate binders and greater systematic vitamin D supplementation-may have influenced the results. The number of patients included in the study is relatively small. Finally, only a C-terminal FGF-23 assay was used; intact FGF-23 assays, which are more specific for the active molecule, were not available.
Conclusion
This study demonstrated high serum FGF-23 levels in LHD patients, despite less hyperphosphataemia. Higher serum FGF-23 levels are associated with increased mortality, which is independent of the serum phosphate level but related to VC. However, together with warfarin, secondary HPT and its treatments, the main factor associated with high serum FGF-23 levels is still phosphataemia, which may appear paradoxical. FGF-23 could be a useful marker of mortality risk in ESRD patients that better reflects phosphate overload, which is only partially reversed by LHD. The identification of patients with high FGF-23 levels, even those with phosphates within the recommended range, may indicate the need for more aggressive phosphate control. However, whether FGF-23 is biologically active or inactive in HD patients remains to be established.
